



The total number of shares in issue at Admission is 152,701,897.

The total voting rights ("TVR") at Admission is 150,357,744*.

Shareholders will be notified of any change in TVR (whether arising as a result of changes in the issued share capital or the application of limitations on the voting rights of certain shareholders) and should use the notified TVR number as the denominator in calculating their voting rights for the purposes of DTR 5.

As at Admission, there are CSOP options outstanding over 3,353,038 Ordinary Shares. Upon exercise in full, such options would represent 2.2 percent of the fully diluted issued share capital.

Substantial Shareholders Following Admission		
Shareholder	Number of Ordinary Shares	Percentage of Share Capital
NorTrust Nominees Limited ⁽¹⁾ (Account WIZ01)	32,250,000	21.12%
NorTrust Nominees Limited ⁽²⁾ (Account WIX01)	32,173,913	20.74%
Cruisen Ltd	14,500,000	9.50%
The Wales Life Sciences Investment Fund LP	10,000,000	6.55%
Global Healthcare Limited	7,000,000	4.58%
Smart Profit Limited	6,956,522	4.56%
WND Holding Ltd	6,956,522	4.56%
Ion Beam Applications S.A.	5,000,000	3.27%
Western Provident Association	5,000,000	3.27%

1. Woodford Patient Capital Trust plc
2. LF Woodford Equity Income Fund

* Due to the limitation on voting rights applying to the holding of LF Woodford Equity Income Fund, as described in more detail in the Admission Document dated 25 February 2019.